SIGA Technologies, Inc.

NASDAQ:SIGA

Drug Manufacturers - Specialty & Generic

Healthcare
$2.80 -0.36%

-$0.02 today

Market cap
$201.19M
Beta
0.85
P/E (TTM)
15.2
EPS (TTM)
$0.28
Dividend yield
13.97%
52W Low $4.10High $9.62

Volume 0.37M

Average 0.61M

SIGA Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

SIGA Technologies, Inc.NASDAQ: SIGA

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$1.24M, compared with $13.98M a year earlier. Trailing-twelve-month accounts receivables was $2.68M. Over 3 fiscal years it compounded at -22.4% a year.

Context

  • Accounts receivables amounted to 18.9% of revenue in FY2025, up 18.9 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near -$1.24M or moves back toward the trailing-twelve-month quarterly average of $670.95K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.24M+60.0% QoQ
Last fiscal yearDec 2025
$17.9M+50990.9% YoY
LTMMar 2026
$2.68M-75.5% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-108.9%——
1 year+50990.9%——
3-year CAGR-22.4%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
17.9M USD
Year-over-year change
+50990.9%

Accounts Receivables vs competitors

How SIGA compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -75.5% is the 7th highest of 8, against a peer median of +54.1%.
  • Accounts receivables amounts to 2.9% of revenue for SIGA, versus a peer median of 5.5%.
SIGA Competitors
Accounts Receivables for SIGA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$59.9M USD+225.6%-40.0%8.9%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$51.06M USD+91.4%+77.2%12.2%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$16.97M USD+54.1%+136.4%3.3%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$8.4M USD-40.2%-25.8%2.8%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$3.65M USD+482.9%—7.3%
SIGASIGA Technologies, Inc.LTM Mar 2026$2.68M USD-75.5%-22.4%2.9%
DRIODarioHealth Corp.LTM Mar 2026$1.61M USD-73.6%—7.6%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$1.31M USD-88.3%—3.7%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
SNDLSNDL Inc.LTM Mar 2026CA$0 CAD——0.0%
Peer median (excluding SIGA) —+54.1%+25.7%5.5%

Competitors are the stored peer set for SIGA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income69.45M33.9M68.07M59.21M23.28M
Depreciation & Amortization522.37K517.64K538.29K538.42K562.61K
Deferred Income Tax121.45K(3.83M)(4.8M)193.42K6.43M
Stock-Based Compensation1.27M1.78M2.05M3.64M3.68M
Change in Working Capital(60.37M)9.44M28.36M(4.69M)8.26M
Accounts Receivables(80.31M)38.24M24.28M(35.18K)17.9M
Inventory136.37K(19.96M)(25.52M)15.34M(846.31K)
Accounts Payables1.47M2.07M2M(5.74M)(578.64K)
Other Working Capital18.34M(10.91M)27.61M(14.26M)(8.22M)
Other Non-Cash Items501K(199.19K)579.24K(10.13M)1.26M
Operating Cash Flow11.49M41.61M94.8M48.76M43.47M
Capital Expenditures(50.62K)0(21.69K)(42.45K)(355.01K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(50.62K)0(21.69K)(42.45K)(355.01K)
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased(26.02M)(13.01M)(11.07M)(799.9K)0
Dividends Paid0(32.94M)(32.14M)(42.67M)(43.12M)
Other Financing Activities(173.92K)(12.53K)(214.79K)0(433.76K)
Financing Cash Flow(26.2M)(45.96M)(43.42M)(43.46M)(43.55M)
Effect of Forex Changes00000
Net Change in Cash(14.75M)(4.35M)51.36M5.25M(433.85K)
Free Cash Flow11.44M41.61M94.78M48.72M43.12M

SIGA Technologies, Inc.

NASDAQ:SIGA

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.